Skip to content
Screener

Novavax NVAX Debt-to-equity

Debt-to-equity at other companies

Moderna logo
ModernaMRNA
0.2×+0.1×
Vaxcyte, Inc. logo
Vaxcyte, Inc.PCVX
0×0.0×
Merck & Co. logo
Merck & Co.MRK
1.4×+0.6×
ALN
Alnylam PharmaceuticalsALNY
0.2×-0.9×
Roivant Sciences logo
Roivant SciencesROIV
0×0.0×
Gilead Sciences logo
Gilead SciencesGILD
2.2×+1.0×

Other financials

Income statement

See full
Revenue$56.7M-76.3%
Gross profit$42.5M-81.0%
Operating income-$54.9M-154%
Net income-$53.4M-150%
EPS (diluted)-$0.32-152%

Balance sheet

See full
Cash & equivalents$191.5M-24.5%
Total debt$297.3M+413%
Total equity-$190.7M-607%
Total assets$955.6M-28.5%

Cash flow

See full
Operating cash flow-$72.8M+42.9%
CapEx$588.0K+11.6%
Free cash flow-$73.4M+42.7%

Valuation

See full
Market cap$1.27B+3.7%
Enterprise value$1.38B+33.6%
P/S3.1×+1.9×

Profitability

See full
Gross margin78.6%-9.6pp
Operating margin-56.6%-89.2pp
Net margin-59.9%-99.1pp
FCF margin-59%-61.5pp

Returns & leverage

See full
Return on equity-238.6%—
Current ratio2.3×0.0×

Where this comes from

Calculated from Novavax’s reported figures.

total debt/total stockholders equity=1.5×

Based on the most recent quarter.

The source filing: Novavax’s 10-Q, filed August 6, 2025. Open the filing →

Filed
Aug 6, 2025
Fiscal quarter
Q2 FY2025
Calendar quarter
Q2 2025
Accession
0001000694-25-000029

FAQ

What is Novavax's debt-to-equity?
Novavax (NVAX) reported debt-to-equity of 1.5× in Q2 2025.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.

Ask your AI about Novavax's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude